First phase of 18-acre, master-planned district quickly takes shape off Northside Drive

A year after breaking ground, the towering lab portion of Georgia Tech’s westward march has officially topped out.

The master-planned Science Square district—an initiative by Georgia Tech and its development partners that’s been in the works for more than a decade—will eventually cover 18 acres on the Westside, offering a blend of uses project leaders say is unlike anything else in Atlanta.

The university picked national developer Trammell Crow Company and its multifamily subsidiary, High Street Residential, to build Science Square in 2021. Georgia Tech affiliate Georgia Advance Technology Ventures is another partner in the project’s two-building initial phase.

The Science Square district’s first phase, which broke ground in August 2022, is rising a total of 27 stories between Georgia Tech’s campus and Westside neighborhoods such as English Avenue, where another multifaceted district,  Echo Street West , began opening last year. Its goal is to fuse biomedical research and technology space with more traditional mixed-use components—commercial spaces and apartments.

Phase one’s 13-story Class A lab and office tower called Science Square Labs, a 368,000-square-foot spec project designed by Perkins + Will and developed by TCC, has recently topped out and made its first lease officially official. 

Photo of Georgia Tech's Science Square project under construction

Chicago-based  Portal Innovations , a venture capital firm that aims to help life sciences companies grow with lab space, seed capital, and management support, has leased the full 10th floor of the labs building, taking 33,136 square feet, TCC reps announced today.

Katherine Lynch, a TCC Atlanta principal, said Atlanta marks the fourth market where Portal will establish “a biotech and medtech ecosystem, further advancing Atlanta’s strong position in the life science industry,” according to a prepared statement. Portal’s space at Science Square will include private offices, wet and dry labs, and collaborative space, alongside an outdoor terrace.

KEEP READING: https://atlanta.urbanize.city/post/georgia-tech-science-square-project-tops-out-images

MORE ARTICLES:

Georgia Life Sciences Designates City of Atlanta as Newest BioReady® Community

By Sheran Brown • February 21, 2025
Georgia Life Sciences Designates City of Atlanta as Newest BioReady® Community

Bipartisan PBM Reform Back in Focus as House Committee Plans Hearing

By Sheran Brown • February 20, 2025
A renewed push for prescription drug cost reform is gaining momentum in Congress, with the House Energy and Commerce Committee's health subcommittee planning a hearing on pharmacy benefit manager (PBM) reform for late February. The hearing, to be led by Rep. Buddy Carter (R-Ga.), signals a revival of bipartisan efforts to regulate these pharmaceutical intermediaries. PBMs, which negotiate drug prices for insurers and employers, have become a focal point in the broader discussion of healthcare costs. A previous bipartisan agreement to regulate these entities was crafted by Carter and Rep. Diana DeGette (D-Colo.) in the last Congress, though it ultimately stalled when the larger spending bill it was attached to faced opposition. The reform efforts enjoy broad support from both parties and the president, making it one of the few areas with potential for bipartisan cooperation. However, new complications have emerged as Republicans consider using PBM regulations to generate savings for their broader policy agenda, potentially requiring up to $880 billion in cost reductions. The path forward remains uncertain, with ongoing debates about whether such reforms would qualify for budget reconciliation and whether using PBM regulations as a funding mechanism could derail bipartisan cooperation. Meanwhile, stakeholders continue to disagree on the impact of additional PBM regulation, with pharmaceutical companies arguing that PBMs inflate drug costs while PBMs contend that new regulations would increase prices.

Council on State Biotechnology Associations says NIH funds are a critical component of innovation ecosystem

By Sheran Brown • February 20, 2025
The Council of State Biotechnology Associations (CSBA) has issued a strong warning about proposed cuts to National Institutes of Health (NIH) funding, emphasizing the critical role these grants play in America's biotech innovation ecosystem. The statement, below , comes amid concerns over recent guidance that would reduce NIH funding to key research institutions. ----------------------- “Today, the US biotech industry employs nearly 2.3 million people across the US and is making positive contributions to economic impact and national security across all 50 states. In fact, for every dollar the National Institutes of Health (NIH) contributes to a successful drug, the private sector invests over $65, underscoring the agency’s unparalleled return on investment. As the associations representing the bioscience industry across the nation, the Council on State Biotechnology Associations (CSBA) is concerned by recent guidance that would cut funding provided by the NIH to universities, hospitals, and other institutions that perform critical early-stage research. NIH grant funds are a critical component of our innovation ecosystem. Grants for basic research are the spark that leads to university-driven discoveries, with public-private partnerships and tech transfers that bridge early-stage research to industry-sponsored drug development and ultimately to FDA approved medical advances for hundreds of diseases. While the administration looks for greater efficiency in the use of taxpayer dollars, it cannot be overstated - once scientific innovation moves abroad, it may never return. In the race for scientific innovation around the world, as our adversaries continue to increase government investments in research, we encourage President Trump to follow suit and ensure that we maintain our global leadership in an industry that was created and thrives across the US.”
MORE POSTS
Share by: